ALS drug maker walks back plan to profit from right-to-try law following heavy criticism
ALS drug maker walks back plan to profit from right-to-try law following heavy criticism.
In the end, BrainStorm Cell Therapeutics’ dalliance with the newly enacted right-to-try law was little more than a publicity stunt.
On Tuesday, the small biotech company said it would not offer its experimental stem cell therapy to patients with amyotrophic lateral
